24/7 Market News- Addex and Indivior Select Clinical Candidates from GABAB PAM Research Collaboration
DENVER, Colo., Aug 27, 2024 (247marketnews.com)- Addex Therapeutics (NASDAQ: ADXN) and Indivior PLC (NASDAQ: INDV) stated that they selected clinical candidates from their GABAB positive allosteric modulator (PAM) research collaboration. Indivior selected a compound to develop for substance use disorder and, per the agreement terms, Addex is eligible for payment of up to $330 million on successful achievement of prespecified regulatory, clinical and commercial milestones, as well as tiered sales royalties.
Indivior’s Chief Scientific Officer, Christian Heidbreder, commented, “Indivior’s collaboration with Addex has been instrumental in identifying a possible candidate for the treatment of substance use disorders.
“While the challenges of this field are complex, targeting the GABAB receptor with positive allosteric modulators offers a potential new avenue for developing much needed therapies. At Indivior, we are committed to advancing the science of addiction treatment, with the goal of bringing effective therapies to those affected by substance use disorders.”
Addex Tim Dyer, CEO of Addex, added, “The selection of GABAB PAM clinical candidates is the culmination of more than five years of research at Addex in close collaboration with the team at Indivior. During this time, we were able to pinpoint specific candidates from thousands of compounds using the power of our industrial-scale allosteric modulator discovery platform. We look forward to the next steps in the development of the substance use disorder program under the control of Indivior.
“On the Addex side, we are now focused on advancing our selected clinical candidate for chronic cough into IND enabling studies.”
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com